Teijin Pharma President To Become Group President
This article was originally published in PharmAsia News
Teijin Pharma President Nario Oyagi is slated to be the new president of Teijin Group, and he is scheduled to be elected during the June 20 shareholders meeting. Oyagi joined the firm in 1971; he has since served as director for medical planning and general manager of medical business. Oyagi became president of Teijin Pharma in 2003. Discussing future visions for Teijin Pharma, Oyagi expects to expand worldwide into the home healthcare arena. Teijin Pharma has established an office in New York City, and it will actively promote business in America, Europe and Asia. (Click here for more-Japanese language
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.